SLRX - צמיחת רווחי EPS רבעונית Salarius Pharmaceuticals, Inc.

The quarterly EPS growth rate reflects the R&D staffing dynamics of biologists and oncologists at Salarius Pharmaceuticals (SLRX). Such fluctuations are driven by partnerships with institutes specializing in the therapy of rare sarcomas and leukemias. However, liquidity shortages and regulatory risks are creating pressure; therefore, the value of 83.60 captures this metric, indicating a critical threshold for the business's financial stability.
פילוחי מדדים פיננסיים ומדדי שוק עבור Salarius Pharmaceuticals (SLRX)

Fundamental asset selection requires an analysis of net income per share dynamics to evaluate capital management efficiency. This indicator captures the percentage change in EPS between quarters, which, under the austerity measures at Salarius Pharmaceuticals (SLRX), allows for tracking the impact of cost reductions on financial results by analyzing the quarterly EPS growth trend.